使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to Align Technology's First Quarter 2016 Earnings Conference Call. (Operator instructions) I will now turn the conference over to your host, Shirley Stacy, VP, Corporate and Investor Communications. Thank you, you may now begin.
各位好,歡迎參加 Align Technology 2016 年第一季財報電話會議。(接線員指示)我現在把會議交給今天的主持人——企業與投資人溝通副總裁 Shirley Stacy。謝謝,您現在可以開始。
Shirley Stacy - VP, Corporate Communication & Investor Relations
Shirley Stacy - VP, Corporate Communication & Investor Relations
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communication and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO, and David White, CFO.
各位午安,感謝各位加入我們。我是 Shirley Stacy,企業溝通與投資人關係副總裁。今天與我一同出席電話會議的有總裁暨執行長 Joe Hogan,以及財務長 David White。
We issued First Quarter 2016 financial results today via Marketwired, which is available on our website at investor. AlignTech.com. Today's conference call is being audio webcast, and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on May 5. To access the telephone replay, domestic callers should dial (877) 660-6853, with conference number 13634117, followed by pound. International callers should dial (201) 612-7415 with the same conference number.
我們今天已透過 Marketwired 發布 2016 年第一季財務結果,相關資訊可在我們的網站 investor.AlignTech.com 查閱。今天的電話會議將以音訊網路直播,並會在我們網站上存檔約 12 個月。電話重播預計將於今日約美東時間下午 5:30 提供,並持續至 5 月 5 日美東時間下午 5:30。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook, and the expected financial results for the second quarter of 2016. These forward-looking statements are only predictions, and involve risks and uncertainties that are set forth in more detail in our recent periodic report filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We have posted a set of GAAP and non-GAAP historical financial statements, including the corresponding reconciliations, and our first quarter conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
提醒各位,今天簡報人員所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2016 年第二季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們近期向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。我們已在網站「Quarterly Results」專區張貼一套 GAAP 與非 GAAP 歷史財務報表(含相對應調節表),以及第一季電話會議簡報投影片。如需更詳細資訊,請參閱上述檔案。
With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some financial highlights and then briefly discuss the performance of our two operating segments, Invisalign Clear Aligners, and scanners. Dave will provide more detail on our financials, and also discuss our outlook for the second quarter. Following that, I'll come back and summarize a few key points, and open up the call to questions.
謝謝你,Shirley。各位午安,感謝各位參與。在今天的電話會議中,我會先提供一些財務重點,接著簡要說明我們兩個營運事業部門的表現:Invisalign 隱形矯正器與掃描器。Dave 將更詳細說明我們的財務狀況,並討論第二季展望。之後我會回來總結幾個重點,並開放提問。
Q1 was a solid start to 2016, with better-than-expected revenue and earnings driven by continued strong year-over-year Invisalign volume across our entire customer base, with North America up 21% and international up 34%. Demand for our new iTero Element scanner remains strong, driving a 72% year-over-year growth in scanner and services revenues.
第一季為 2016 年帶來穩健的開局;在我們整體客戶群 Invisalign 量能持續強勁年增的帶動下,營收與獲利優於預期,其中北美年增 21%,國際年增 34%。我們新款 iTero Element 掃描器需求仍然強勁,帶動掃描器與服務營收年增 72%。
For Q1, North America clear aligner volume was up both sequentially and year-over-year. On a sequential basis, Q1 was driven primarily by our North American orthodontist customers, who achieved record utilization of 10.4 cases per doctor this quarter. On a year-over-year basis, our Q1 volume growth rate continues to outpace the three-year average, and was driven by continued increase in ortho utilization, and expansion of our GP customer base.
第一季北美隱形矯正器量能無論較前一季或較去年同期皆成長。以季增來看,第一季主要由北美矯正專科客戶帶動,本季每位醫師平均使用量達到創紀錄的 10.4 例。以年增來看,我們第一季的量能成長率持續高於三年平均,主要來自矯正專科使用量持續提升,以及一般牙醫(GP)客戶基礎的擴張。
Q1 Invisalign volume for international doctors was down 1.5% sequentially, as expected, given the seasonally lower period in Europe due to winter holidays and up to 34% year-over-year.
國際醫師第一季 Invisalign 量能如預期較前一季下滑 1.5%,原因是歐洲冬季假期使該期間季節性較淡;但較去年同期則成長 34%。
In EMEA Q1, volume was up 34% year-over-year, led by growth across our core European countries, and was especially strong in Spain, which was up 70%. Investments made in sales, clinical and customer care, with our new selling processes, are showing quick returns. Our new geographies also performed well year-over-year with Benelux, Eastern Europe and the Nordic markets up over 90%.
在 EMEA 地區第一季,量能較去年同期成長 34%,主要由歐洲核心國家帶動;其中西班牙表現尤其強勁,成長 70%。我們在銷售、臨床與客戶關懷方面的投資,以及新的銷售流程,正快速展現回報。我們的新市場同樣有良好年增表現:比荷盧、東歐與北歐市場成長皆超過 90%。
In Asia-Pacific, total Q1 volume was 35% year-over-year led by China and Japan, each of which were up 50% or more. Record Invisalign volume in both Southeast Asia and Taiwan was driven by growth of more than 40% year-over-year, as they continued to make progress in smaller country markets with our direct sales approach.
在亞太地區,第一季總量能較去年同期成長 35%,主要由中國與日本帶動,兩者皆成長 50% 或以上。東南亞與台灣的 Invisalign 量能亦創新高,年增超過 40%;我們透過直營銷售模式,持續在較小的國家市場取得進展。
Next month in Macau, we look forward to hosting our second Invisalign APAC summit, where almost 700 customers will attend the largest Invisalign summit outside of North America. The APAC summit will focus heavily on recent innovations, Invisalign advantages over other treatment options, and peer-to-peer sharing of successful treatment outcomes in very complex cases.
下個月在澳門,我們期待主辦第二屆 Invisalign 亞太高峰會,屆時將有近 700 位客戶出席,這將是北美以外規模最大的 Invisalign 高峰會。亞太高峰會將著重於近期創新、Invisalign 相較其他治療選項的優勢,以及同儕之間分享在高度複雜病例中成功的治療成果。
In the important teen segment, the total number of Invisalign cases worldwide in Q1 increased 22% year-over-year, reflecting continued adoption of Invisalign treatment for teenagers 11 to 19 years old. On a 12-month basis, 148,000 teens started orthodontic treatment with Invisalign with an average age of 15 years. We are pleased with continued growth in teenage cases, especially among North American orthos. We're also beginning to make progress in growing our teen business outside the United States, where we had 30% year-over-year growth from international doctors.
在重要的青少年族群方面,第一季全球 Invisalign 青少年病例總數較去年同期增加 22%,反映 11 至 19 歲青少年對 Invisalign 治療的持續採用。以過去 12 個月計,有 148,000 名青少年以 Invisalign 開始矯正治療,平均年齡為 15 歲。我們對青少年病例的持續成長感到滿意,尤其是在北美矯正專科醫師族群。我們也開始在美國以外市場推動青少年業務成長取得進展,國際醫師帶來的年增達 30%。
Our integrated customer marketing campaigns in North America, EMEA and APAC leveraged traditional paid media, search, digital marketing, PR and social media to engage consumers at every point in the consumer purchasing journey. Consumers' interest and demand for Invisalign treatment continues to grow, as we can see from the increase in key program metrics worldwide. For example, in Q1, the total number of unique web visitors to Invisalign.com or its regional equivalent increased 30% to 3 million, and the total number of consumers who search for an Invisalign provider increased 27% to nearly a half a million. North America 2016 marked the strongest Q1 to date for the Invisalign brand in terms of earned media with 27% increase in overall impressions.
我們在北美、EMEA 與 APAC 的整合式客戶行銷活動,結合傳統付費媒體、搜尋、數位行銷、公關與社群媒體,在消費者購買旅程的每個環節與其互動。消費者對 Invisalign 治療的興趣與需求持續成長,從全球關鍵計畫指標的提升即可看出。例如第一季,造訪 Invisalign.com 或各地區對應網站的不重複訪客總數增加 30% 至 300 萬;搜尋 Invisalign 醫師提供者的消費者總數增加 27% 至接近 50 萬。北美 2016 年第一季在「贏得媒體」方面創下 Invisalign 品牌歷來最強的第一季,整體曝光量增加 27%。
In EMEA, we focused primarily on lead generation activities in Q1, which drove 670,000 visitors to regional Invisalign websites, and our Invisalign social media community grew significantly, up 150% compared to Q1 last year. In Asia-Pacific, we've been preparing for several major consumer campaigns in China, Australia/New Zealand, and Japan, that will launch in Q2. The new campaign in China will be our very first in the country, targeting females 25 years and older in both Shanghai and Beijing.
在 EMEA,我們第一季主要聚焦於名單開發活動,帶動 670,000 名訪客造訪區域 Invisalign 網站;同時我們的 Invisalign 社群媒體社群顯著成長,較去年第一季增加 150%。在亞太地區,我們正為中國、澳洲/紐西蘭與日本的多項大型消費者行銷活動做準備,並將於第二季推出。中國的新活動將是我們在該國的首次行銷活動,鎖定上海與北京兩地 25 歲以上女性。
In Q1, our scanners business revenue was up 17% sequentially and 72% year-over-year, reflecting a record number of units shipped in a quarter. Demand for the iTero Element scanner continues to expand our installed base, fueled primarily by North American orthodontists.
第一季,我們掃描器事業營收較前一季成長 17%,較去年同期成長 72%,反映單季出貨台數創新高。iTero Element 掃描器的需求持續擴大我們的裝機基礎,主要由北美矯正專科醫師帶動。
As of Q1, 94% of our top 1% elite orthos have purchased at least one scanner, and 64% of our top 1% elite GPs have purchased a scanner for their practice. We also continue to see strong adoption of digital scanners for Invisalign case submissions in place of PVS impressions. For Q1, total Invisalign cases submitted with a digital scanning worldwide increased to 36%, which reflects a record 44% from North America and 18% from international doctors. While these scans are predominantly from our iTero scanner, we're beginning to see some uptake from 3M's Tru Def and Sirona's Omnicam, the other two digital scanners that also qualify for Invisalign case submission.
截至第一季,我們前1%菁英矯正醫師中有94%已購買至少一台掃描器,而我們前1%菁英一般牙醫(GP)中有64%已為其診所購買掃描器。我們也持續看到在提交 Invisalign 病例時,以數位掃描器取代 PVS 印模的採用度強勁提升。第一季全球以數位掃描提交的 Invisalign 病例占比提升至36%,其中北美創下44%的紀錄,國際醫師為18%。雖然這些掃描主要來自我們的 iTero 掃描器,但我們也開始看到來自 3M 的 Tru Def 與 Sirona 的 Omnicam 的一些採用;這兩款也是符合 Invisalign 病例提交資格的另外兩種數位掃描器。
Adding to this today, we announce Invisalign interoperability with another third-party scanner. In Q4 of this year, three of 3Shape's scanners are expected to be approved, which will enable Invisalign providers with a TRIOS scanner to submit a full arch digital impression in place of a traditional PVS impression. Clinical validation of the workflow is mostly complete, however, given our ERP implementation this summer, the ability to support TRIOS scanners for Invisalign case submission cannot be finalized in our Invisalign doctor site, which we call IDS, until after the ERP implementation is complete.
在此基礎上,我們今天宣布 Invisalign 與另一家第三方掃描器的互通性。預計在今年第四季,3Shape 的三款掃描器將獲得核准,這將使配備 TRIOS 掃描器的 Invisalign 提供者能以全口弓數位印模取代傳統 PVS 印模來提交病例。該工作流程的臨床驗證大多已完成;然而,鑑於我們今年夏季的 ERP 導入,在我們稱為 IDS 的 Invisalign 醫師網站上支援 TRIOS 掃描器進行 Invisalign 病例提交的能力,必須待 ERP 導入完成後才能定案。
We also announced an agreement with 3Shape to enhance existing STL export workflow between iTero scanners and laboratory partners using 3Shape Dental Systems software. This will enable improved consistency for customers using the workflow. With that, I'll now turn the call over to David.
我們也宣布與 3Shape 達成協議,以強化 iTero 掃描器與使用 3Shape Dental Systems 軟體的實驗室合作夥伴之間既有的 STL 匯出工作流程。這將使採用該工作流程的客戶獲得更佳的一致性。接下來,我把電話會議交給 David。
David White - CFO
David White - CFO
Thanks, Joe. Let's review our first quarter financial results.
謝謝,Joe。讓我們回顧第一季的財務結果。
Revenue for the first quarter was $238.7 million, up 3.7% from the prior quarter, and up 20.5% from the corresponding quarter a year ago. On a year-over-year comparative basis, first quarter revenue growth rate was lower by approximately 5 points related to the Additional Aligner policy and the impact of foreign currency exchange rates.
第一季營收為2.387億美元,較前一季成長3.7%,較去年同期成長20.5%。以年對年比較而言,第一季營收成長率因 Additional Aligner 政策以及外匯匯率影響而約低了5個百分點。
First quarter clear aligner revenue of $219.7 million was up 2.6% sequentially, and up 17.5% year-over-year. The sequential revenue increase was primarily related to increased clear aligner volumes.
第一季透明牙套營收為2.197億美元,較前一季成長2.6%,較去年同期成長17.5%。營收的季對季增加主要與透明牙套出貨量增加有關。
Q1 ASPs were slightly up from Q4 about $5, due to more Additional Aligner submissions and fewer promotions, partially offset by foreign exchange rates and a small shift in product mix towards our low end products, driven by the Single Arch option we introduced last year.
第一季 ASP 較第四季小幅上升約5美元,原因是 Additional Aligner 提交增加且促銷減少;但部分被外匯匯率以及產品組合小幅轉向低階產品所抵銷,而此一轉變係由我們去年推出的單弓(Single Arch)選項所帶動。
Our year-over-year revenue growth reflected Invisalign case volume growth across all customer channels and geographies, partially offset by lower ASPs primarily related to Additional Aligner policy change and foreign exchange rates.
我們的年對年營收成長反映 Invisalign 病例量在所有客戶通路與各地區皆成長,但部分被 ASP 下滑所抵銷;ASP 下滑主要與 Additional Aligner 政策變更及外匯匯率有關。
For the first quarter, total Invisalign shipments of 163.7 thousand cases were up 2.1% sequentially, reflecting growth predominantly from our North American orthodontist customers. Year-over-year case volume growth was 25.2%, driven by growth across all regions.
第一季 Invisalign 總出貨量為16.37萬例,較前一季成長2.1%,成長主要來自北美矯正醫師客戶。年對年病例量成長25.2%,由各區域的成長所帶動。
For North American orthodontists, Q1 Invisalign case volume was up 7% sequentially, reflecting higher adoption and utilization rates across the channel, and up 23.6% year-over-year. For North American GP dentists, case volume was flat sequentially and up 18.6% year-over-year. For international doctors, Invisalign case volume was seasonally down 1.5% sequentially, and up 34.1% year-over-year.
就北美矯正醫師而言,第一季 Invisalign 病例量較前一季成長7%,反映該通路的採用率與使用率提升,且較去年同期成長23.6%。就北美一般牙醫(GP)而言,病例量季對季持平,年對年成長18.6%。就國際醫師而言,Invisalign 病例量因季節性因素季對季下滑1.5%,但年對年成長34.1%。
Worldwide Invisalign utilization in Q1 was 4.9 cases per doctor, up from 4.5 in Q1 last year. North America ortho utilization was a record 10.4, up from 9 in the prior year. North America GP utilization was 3, up from 2.9 in the prior year, and international utilization was 4.7, also a record, up from 4.4 cases per doctor in Q1 last year.
第一季全球 Invisalign 平均使用量為每位醫師4.9例,高於去年第一季的4.5例。北美矯正醫師使用量創下每位10.4例的紀錄,高於前一年的9例。北美一般牙醫(GP)使用量為3例,高於前一年的2.9例;國際使用量為4.7例,同樣創紀錄,高於去年第一季每位醫師4.4例。
In Q1, we added 2,470 new Invisalign doctors worldwide, 870 of which were new North American doctors and 1,600 of which were new international doctors.
第一季我們在全球新增2,470位 Invisalign 醫師,其中870位為北美新醫師,1,600位為國際新醫師。
Our scanner and services revenue for the first quarter was $19 million, up 17.2% sequentially, and 72% year-over-year. We're pleased with continued strong demand for the iTero Element scanner. Notwithstanding these strong results, production capacity has been more constrained than expected as we strive to ramp production and work down backlog.
第一季掃描器與服務營收為1,900萬美元,較前一季成長17.2%,較去年同期成長72%。我們對 iTero Element 掃描器持續強勁的需求感到滿意。儘管成果亮眼,當我們努力提升產能並消化積壓訂單時,生產產能的受限程度仍高於預期。
Moving on to gross margin, first quarter overall gross margin was 75.7%, slightly better than expected, up 0.7 points sequentially and down 0.6 points year-over-year. Clear aligner gross margin for the first quarter was 78.3%, up 0.4 points sequentially and down 0.8 points year-over-year. The sequential increase was primarily driven by lower freight costs from a slightly lower mix of international shipments. The year-over-year decrease in gross margin was primarily the result of lower clear aligner ASPs related to our new Additional Aligner policy implemented in July of last year.
接著看毛利率,第一季整體毛利率為75.7%,略優於預期,較前一季提升0.7個百分點,較去年同期下降0.6個百分點。第一季透明牙套毛利率為78.3%,較前一季提升0.4個百分點,較去年同期下降0.8個百分點。季對季提升主要由於國際出貨占比略降,帶動運費成本降低。年對年毛利率下降主要是因去年7月實施的新 Additional Aligner 政策導致透明牙套 ASP 降低。
Q1 gross margin for our scanner segment was a record 45%, up 7.3 points sequentially and 16.7 points year-over-year. Both the sequential and year-over-year increase in gross margin was primarily a result of higher ASPs and lower cost of our iTero Element scanner.
第一季我們掃描器部門毛利率創下45%的紀錄,較前一季提升7.3個百分點,較去年同期提升16.7個百分點。無論季對季或年對年毛利率提升,主要皆源於 ASP 較高以及 iTero Element 掃描器成本較低。
Q1 operating expenses were $127.3 million, up sequentially by $13.8 million, or 12.2%, primarily due to the planned annual increases in employee compensation and benefits programs, costs associated with our internal sales meeting events that take place in Q1, increased investments in sales and marketing and go-to-market activities, as well as our ERP implementation program.
第一季營業費用為1.273億美元,較前一季增加1,380萬美元(或12.2%),主要由於員工薪酬與福利方案的年度計畫性調升、第一季舉行的內部銷售會議活動相關成本、對銷售與行銷及上市(go-to-market)活動的投資增加,以及我們的 ERP 導入計畫。
Q1 operating expenses were lower than our outlook, due primarily to more ERP costs being capitalized than anticipated during the quarter. In addition, the timing of certain investments in marketing were delayed to the second quarter and second half of the year.
第一季營業費用低於我們的展望,主要因本季資本化的 ERP 成本高於預期。此外,部分行銷投資的時程延後至第二季及下半年。
On a year-over-year basis, Q1 operating expenses were up $25.1 million, or 24.6%, reflecting increased head count and continued investment in go-to-market activities incidental to the growth of our business, as well as our ERP implementation project.
以年對年而言,第一季營業費用增加2,510萬美元(或24.6%),反映人員編制增加、隨業務成長而持續投入上市(go-to-market)活動,以及我們的 ERP 導入專案。
Also recall that in the first quarter last year, operating expenses included a benefit of $6.8 million associated with a medical device excise tax refund.
另外請記得,去年第一季的營業費用包含與醫療器材消費稅退稅相關的680萬美元利益。
Our first quarter operating margin was 22.3%, down 3.5 points sequentially and down 2.4 points year-over-year. This sequential decrease in operating margin relates primarily to higher expenses as just described. On a year-over-year basis, Q1 operating margin was impacted by approximately 2.5 points from the Additional Aligner policy, and foreign currency exchange. Also note again that the year-over-year comparison reflects the aforementioned benefit of the medical device excise tax in Q1 2015.
第一季營業利益率為22.3%,較前一季下降3.5個百分點,較去年同期下降2.4個百分點。營業利益率的季對季下降主要與前述費用增加有關。以年對年而言,第一季營業利益率約受到 Additional Aligner 政策及外匯匯率影響約2.5個百分點。也請再次注意,年對年比較亦反映前述2015年第一季醫療器材消費稅的利益。
With regards to our first quarter tax provision, our tax rate was 23.4%, slightly up from our 2015 tax rate of 22.6%, and 18.2% in Q4 2015. 2015 and Q4 2015 tax rates are lower, primarily a result of lower tax expense related to the true-up incidental to the filing of certain tax returns, and the renewal of the US R&D tax credit in Q4 2015.
關於我們第一季的所得稅提列,我們的稅率為 23.4%,較 2015 年的 22.6% 略高,也高於 2015 年第四季的 18.2%。2015 年及 2015 年第四季的稅率較低,主要是因在申報某些稅表時所進行的調整(true-up)而產生較低的稅費支出,以及 2015 年第四季美國研發(R&D)稅額抵減的續期所致。
First quarter diluted earnings per share was $0.50 compared to $0.60 reported in Q4, and $0.44 reported in the same quarter a year ago. First quarter EPS was impacted by approximately $0.09 per share from the new Additional Aligners policy and the yearly impact of currency. Further recall that the first quarter of last year included a benefit of $0.06 per share associated with the refund of the medical device excise tax.
第一季稀釋每股盈餘為 0.50 美元,相較於第四季報告的 0.60 美元,以及去年同期報告的 0.44 美元。第一季 EPS 受到新「Additional Aligners」政策及匯率年度影響,合計約每股 0.09 美元的影響。另外請記得,去年第一季包含與醫療器材消費稅退稅相關的每股 0.06 美元利益。
Moving on to the balance sheet, capital expenditures for the first quarter were $20.2 million, primarily relating to equipment purchases to expand our manufacturing capacity in Juarez, Mexico, as well as our ERP implementation. Cash flow from operations for the first quarter was $30.7 million, and free cash flow for the first quarter, defined as cash flow from operations less capital expenditures, amounted to $10.5 million.
接著看資產負債表,第一季資本支出為 2,020 萬美元,主要與設備採購有關,用於擴充我們在墨西哥華雷斯(Juarez)的製造產能,以及我們的 ERP 導入。第一季營運活動現金流量為 3,070 萬美元;第一季自由現金流量(定義為營運活動現金流量減資本支出)為 1,050 萬美元。
During the quarter, we also used $22.6 million of cash to pay employee taxes for the net settlement of vesting employee stock awards that otherwise would have been issued. Over the last 12 months, these amounts, together with repurchases, have amounted to $128.6 million.
本季期間,我們也使用 2,260 萬美元現金,用於支付員工稅款,以就原本將發行的員工股票獎酬歸屬部分進行淨額交割。過去 12 個月,這些金額連同庫藏股回購合計達 1.286 億美元。
Today, we announced that our Board of Directors has authorized a plan to repurchase up to an additional $300 million of the Company's stock. This latest authorization is in addition to the existing $300 million authorization announced in April 2014, which brings the total authorization to $600 million. To date, we have purchased approximately $200 million of our stock and anticipate we will repurchase another $100 million over the next 12 months.
今天,我們宣布董事會已核准一項計畫,授權額外回購最多 3 億美元的公司股票。此最新授權係在 2014 年 4 月宣布的既有 3 億美元授權之外,將總授權額提高至 6 億美元。截至目前,我們已回購約 2 億美元的股票,並預期未來 12 個月將再回購 1 億美元。
Cash, cash equivalents and marketable securities including both short- and long-term investments were $680.8 million. This compares to $678.7 million at the end of 2015, an increase of approximately $2.1 million. Of our $680.8 million dollars of cash, cash equivalents and marketable securities, $216 million was held by the US and $464.8 million was held by our international entities.
現金、約當現金及有價證券(包含短期與長期投資)為 6.808 億美元。相較於 2015 年底的 6.787 億美元,約增加 210 萬美元。在我們 6.808 億美元的現金、約當現金及有價證券中,2.16 億美元由美國持有,4.648 億美元由我們的海外實體持有。
With that, let's now turn to our business outlook and the factors that inform our view.
接下來,我們來談談業務展望,以及支撐我們觀點的因素。
Starting with the demand outlook, for North America we expect Invisalign volumes to be up sequentially from Q1. With International, we typically see strong sequential growth following Q1 winter holidays in EMEA and the Lunar New Year in APAC. For our scanner business, we expect revenues to be up sequentially from Q1 as we continue to ramp production for the new iTero Element and fulfill strong backlog and demand. Notwithstanding this strength, given recent and continuing constraints on production of the new iTero Element, our outlook for scanner revenue for the full year is slightly less robust than original anticipated.
先從需求展望談起,在北美,我們預期 Invisalign 出貨量將較第一季呈現季增。在國際市場方面,我們通常會在 EMEA 的第一季冬季假期以及 APAC 的農曆新年之後,看到強勁的季增成長。至於我們的掃描器業務,隨著我們持續提升新 iTero Element 的產能並滿足強勁的積壓訂單與需求,我們預期營收將較第一季呈現季增。儘管需求強勁,鑑於近期且持續的新 iTero Element 產能限制,我們對掃描器全年營收的展望較原先預期略為保守。
With this as a backdrop, we expect the second quarter to shape up as follows. Invisalign case volume is anticipated to be in the range of 174.5 to 177.0 thousand cases, up approximately 20.7% to 22.4% over the same period a year ago. We expect Q2 net revenues to be in the range of $253.3 million to $258.3 million. We expect Q2 gross margins to be in the range of 75% to 75.5%, slightly down sequentially, primarily due to a higher freight cost due to increased mix of international shipments as well as increased training revenue which carries lower gross margins.
在此背景下,我們預期第二季表現如下。Invisalign 病例量預估介於 17.45 萬至 17.70 萬例,較去年同期約成長 20.7% 至 22.4%。我們預期第二季淨營收介於 2.533 億至 2.583 億美元。我們預期第二季毛利率介於 75% 至 75.5%,較前一季略降,主要因國際出貨占比提高導致運費成本較高,以及訓練營收增加(其毛利率較低)。
We expect operating expenses to be in the range of $142.7 million to $144.2 million. Q2 operating expenses will increase quarter-over-quarter based on several factors. Q2 will carry the full-quarter impact of employee compensation-related costs such as annual wage increases, stock-based compensation awards, and new hires. Some investments and sales territory coverage and go-to-market activities that were anticipated in Q1 were delayed to Q2 in the second half of the year. Given our continued success in driving growth and adoption of Invisalign outside the US, we do intend to make some incremental investments in the second half of 2016.
我們預期營業費用介於 1.427 億至 1.442 億美元。第二季營業費用將較前一季增加,原因有數項。第二季將反映員工薪酬相關成本的整季影響,例如年度加薪、以股票為基礎之酬勞獎酬,以及新進人員。原先預期在第一季進行的部分投資、銷售區域覆蓋與上市推廣(go-to-market)活動,延後至第二季及下半年。鑑於我們持續成功推動美國以外市場 Invisalign 的成長與採用,我們確實打算在 2016 年下半年進行一些額外投資。
Our Q2 operating margin should be in the range of 18.7% to 19.7%. Our effective tax rate should be approximately 24%. And diluted shares outstanding should be approximately 81.4 million, exclusive of any share repurchases. Taken together, we expect our Q2 diluted EPS to be in the range of $0.46 to $0.49.
我們第二季營業利益率應介於 18.7% 至 19.7%。我們的有效稅率應約為 24%。稀釋流通在外股數應約為 8,140 萬股,不包含任何股票回購的影響。綜合以上,我們預期第二季稀釋 EPS 介於 0.46 至 0.49 美元。
With that, I'll turn the time back over to Joe for final comment. Joe?
接下來,我把時間交還給 Joe 做最後評論。Joe?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Thanks, David. I'm pleased with Q1 and our better-than-expected start to the year, thanks to continued growth and adoption across our customer base. We credit that to our focus on and investment in key growth drivers, especially our continued expansion outside of North America, commitments of product and technology innovation and consumer demand programs that help drive Invisalign adoption. Q2 will be a busy quarter for us, with the upcoming AAO in Orlando, the APAC Summit in Macau, and our Analyst Day coming up in June. I look forward to seeing many of you at that analyst meeting in New York, and to sharing more details about our opportunities for growth, our competitive advantages, and the key things we're focusing on for the future. Thank you for your time today. I'll now open the call to questions. Operator?
謝謝,David。我對第一季以及我們優於預期的年度開局感到滿意,這要歸功於我們客戶群持續的成長與採用。我們將此歸因於我們聚焦並投資於關鍵成長動能,尤其是持續擴展北美以外市場、對產品與技術創新的投入承諾,以及有助於推動 Invisalign 採用的消費者需求計畫。第二季對我們而言會很忙碌,包括即將在奧蘭多舉行的 AAO、在澳門舉行的 APAC 高峰會,以及 6 月即將到來的分析師日。我期待在紐約的分析師會議上見到各位,並分享更多關於我們成長機會、競爭優勢,以及我們未來重點聚焦事項的細節。感謝各位今天撥冗參與。我現在開放提問。接線生?
Operator
Operator
(Operator instructions) our first question comes from Robert Jones from Goldman Sachs.
(接線生指示) 我們的第一個問題來自高盛(Goldman Sachs)的 Robert Jones。
Robert Jones - Analyst
Robert Jones - Analyst
Thanks for the questions. You guys mentioned that some of the investments were delayed from Q1 to later in the year. I guess the first part would be why were they delayed, and then the second part, more importantly, does that delay in investment have any impact at all on your view of mid-20% revenue growth for the year? Obviously, case growth continues to be pretty strong, and also tied to that level of investment. Just wondering if the timing of the spend has affected at all your view of the full year?
謝謝讓我提問。你們提到有些投資從第一季延後到今年稍晚。我想第一部分是為什麼會延後;第二部分、更重要的是,這樣的投資延後是否會對你們對全年營收中段 20% 成長的看法造成任何影響?顯然病例量成長仍相當強勁,也與該投資水準相關。想請教支出時點是否對你們對全年展望有任何影響?
David White - CFO
David White - CFO
Bob, this is David. I'll see if I can field that for you. They were marketing expenses, as we talked about, as I mentioned in the script. They were, however, though, related to things that had longer-term, had a longer-term aspect to them, so they weren't near-term types of items that would necessarily be driving current-year case growth. They had more to do with portfolio types of planning and studies and things like that, so nothing, no impact to the year.
Bob,我是 David。我來試著回答你的問題。如同我們談到的、我在講稿中也提到,那些是行銷費用。不過,它們與較長期的事項相關,具有較長期的面向,因此並非那種會在短期內直接推動當年度病例量成長的項目。它們更多與產品組合層面的規劃、研究與類似事項有關,所以對今年沒有影響。
Robert Jones - Analyst
Robert Jones - Analyst
Got it, and then I guess just on the international side, case growth, obviously very robust there but kind of in line with the type of growth we've seen in the last few quarters. I know you guys had mentioned more investment this year coming on the international side versus the domestic side. I'm just curious if you could talk about what type of growth rate or growth rate acceleration we should maybe think about on the year's international side, and then maybe just the timeline or timing around the returns on the investments you're making internationally would be helpful.
了解,那我想就國際市場這邊來看,病例成長顯然非常強勁,但大致上也符合我們過去幾季看到的成長型態。我知道你們提到今年相較於國內市場,國際市場會有更多投資。我只是想請教,你們能否談談今年國際市場這邊我們應該如何看待成長率或成長加速的幅度?另外,你們在國際市場所做投資的回收時程或時間點,若能說明也會很有幫助。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
It's Joe, Bob, and I'd say what we expect is to continue with the growth rate we've seen from an international standpoint, so I don't see a change there. You know, and a sense of overall in that business, it's pretty much what we've been telling you. There's not a lot of dilution in the sense of what we do internationally, in the sense of the resources we put in in a year, and the return we're getting on those resources, too. So, think about that return and the aspect of one year kind of return on international commercial kinds of resources.
我是 Joe,Bob,我會說我們預期會延續國際市場這邊我們已經看到的成長率,所以我不認為那裡會有變化。你知道,整體來看,那塊業務基本上就是我們一直跟你們說的狀況。就我們在國際上所做的事情而言,並沒有太多稀釋效應;就一年內投入的資源,以及我們從這些資源取得的回報來看也是如此。所以,可以把它想成國際商業類資源在一年左右就能看到回報的那種回報特性。
Robert Jones - Analyst
Robert Jones - Analyst
Got it. Thanks so much.
了解。非常感謝。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
You're welcome.
不客氣。
Operator
Operator
Thank you. Our next question comes from Steve Beuchaw, from Morgan Stanley.
謝謝。下一個問題來自摩根士丹利(Morgan Stanley)的 Steve Beuchaw。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Thanks for taking the questions, guys. My first one is actually on the buyback. Of course, very nice to see. My question is, are you framing the buyback for 2016 as something like a new normal, or is this something that we should think of as a one-time step up relative to the historical trend?
謝謝讓我提問,各位。我第一個問題其實是關於庫藏股回購。當然,很高興看到這個消息。我的問題是,你們是否把 2016 年的回購視為一種新的常態?還是我們應該把它看作相較於歷史趨勢的一次性上調?
David White - CFO
David White - CFO
So, I don't think there's any intended change in the program that we announced a couple of years ago, Steve. We announced $300 million, we anticipated to repurchase $100 million dollars a year. In the first two years of that program, we repurchased $70 million of the $100 million in each case using an ASR, and then we repurchased the remaining $30 million in open market transactions over the balance of the year. And this year, pretty much the same thing except we're changing it to a 50/50 split. No other change, other than that.
Steve,我不認為我們對幾年前宣布的計畫有任何意圖上的改變。我們宣布的是 3 億美元,並預期每年回購 1 億美元。在該計畫的前兩年,我們每年都用 ASR 回購了 1 億美元中的 7,000 萬美元,然後在當年剩餘期間透過公開市場交易回購剩下的 3,000 萬美元。而今年基本上也是同樣做法,只是我們把它改成 50/50 的分配。除此之外沒有其他改變。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Okay, got it. So, it's not -- okay, now I understand the pure ASA. So, and then my second question actually, David, is could you quantify how much of the spend was delayed out of Q1 into the balance of the year?
好的,了解。所以,不是——好,現在我理解純 ASR 的部分了。那我第二個問題其實是,David,你能否量化一下有多少支出從第一季延後到今年其餘期間?
David White - CFO
David White - CFO
So, the portion that was delayed into Q2 is in our guidance. The portion that was delayed into the second half is about $2 million or so, roughly.
延後到第二季的那部分已反映在我們的指引中。延後到下半年的部分大約是 200 萬美元左右。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Got it. And then, I --
了解。然後,我——
David White - CFO
David White - CFO
Go ahead?
你繼續?
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Thank you very much, have a good night.
非常感謝,祝你們晚安。
David White - CFO
David White - CFO
You bet.
沒問題。
Operator
Operator
Thank you. Our next question comes from John Kreger from William Blair.
謝謝。下一個問題來自 William Blair 的 John Kreger。
John Kreger - Analyst
John Kreger - Analyst
Hi, thanks very much. Joe, can you just maybe give us an update on market commentary? There's been a fair amount of economic volatility in recent months. Are you seeing any of that filter through to your GP or ortho customers?
嗨,非常感謝。Joe,你能否就市場狀況給我們一些最新評論?近幾個月經濟波動相當大。你們是否看到這些情況傳導到你們的一般牙科(GP)或齒顎矯正(ortho)客戶端?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I haven't seen any change at all from what we experienced in 2015, as we go into 2016. Nothing recently, either, in that sense.
就我所見,從 2015 年到進入 2016 年,完全沒有任何變化。最近也沒有看到任何變化。
John Kreger - Analyst
John Kreger - Analyst
So, what does that tell you? Does that say there is just not as much sensitivity around what we would probably think of as a fairly discretionary purchase by consumers, or do you think there's just such an under-penetration for clear aligners that you can kind of power through the cyclicality that an orthodontist might see?
那你怎麼解讀?這是否表示,對於我們可能會認為是消費者相當可自由裁量的購買,敏感度其實沒那麼高?還是你認為透明牙套的滲透率仍然很低,因此你們能夠在矯正醫師可能面臨的景氣循環中持續推進?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I'd be cautious, but you know, I haven't gone through a cycle in this business yet, John. So, I'd just be cautious in what I'd say here. I'd say, if I look at the economic data and back up a little bit, a lot of that economic data has to do with inventory and production right now, and I don't think it's in a consumer sense, something that's definitive yet. So, what I'm seeing right now, what I'm trying to communicate to you, is the market feels now as the market has for the last really 10 months since I've been here. If this thing hits the consumer, and there's a significant consumer effect, I think it'd be naive of us to just say that we think we'll just power through that with the same kind of growth rates we have today. But, I think we've just got to take that a quarter at a time, right now.
我會保持謹慎,但你知道,John,我在這個產業裡還沒有經歷過一個完整的景氣循環。所以我對於在這裡要說什麼會比較保守。我會說,如果我看一下經濟數據並稍微退一步看,很多經濟數據目前其實與庫存和生產有關,我不認為在消費端的意義上,這些數據已經足夠明確。所以我現在看到、也想傳達給你的是,市場的感受跟我來這裡以來、過去大概 10 個月的感受差不多。如果這件事真的影響到消費者,而且對消費端造成顯著衝擊,我們若天真地說我們仍能以今天同樣的成長率一路挺過去,我覺得那是不切實際的。但我想我們現在只能一季一季地觀察。
John Kreger - Analyst
John Kreger - Analyst
Great. Thanks, and then one more, you mentioned the upcoming AAO meeting. It's been a little longer than I think in the past of when you guys have announced some product updates. Any preview you could give us about something that might be coming then, or just in general the cadence that we should expect about new product innovation?
很好。謝謝,另外還有一個問題,你提到即將到來的 AAO 會議。你們宣布一些產品更新的時間點,似乎比過去稍微久一點。你能否先給我們一些預告,屆時可能會有什麼推出?或更一般地說,我們應該如何期待新產品創新的節奏?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
No big change in the cadence of new product introduction. I can't give you any kind of a look under the covers right now in the sense of you know, what we might do at the AAO, John, or not do at the AAO, but look. R&D is incredibly important to us. You know we're focused on malocclusions in the sense of making this a deeper and deeper penetration against wires and brackets. We're really excited about that future portfolio and what we can do, but not ready to announce anything big, you know, coming up on the AAO right now.
新產品導入的節奏沒有重大改變。就你知道的那種「先讓你看一下內部」而言,我現在無法透露我們在 AAO 可能會做什麼或不做什麼,John,但你看。研發對我們極其重要。你知道我們聚焦在咬合不正(malocclusions),也就是讓我們相對於鋼絲與矯正托槽的滲透更深、更廣。我們對未來的產品組合以及我們能做到的事情非常興奮,但目前還沒準備好在即將到來的 AAO 上宣布任何重大消息。
John Kreger - Analyst
John Kreger - Analyst
Okay, great. Thank you.
好的,很好。謝謝。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
You're welcome.
不客氣。
Operator
Operator
Our next question comes from Brandon Couillard from Jefferies.
下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Hey, thanks. Good afternoon. Joe, just a question on the case, the digital case submissions. I'm curious as to your latest thoughts on how much contribution, or how you would characterize the success or progress of the CEREC relationship so far, and just given the installed base size I'm surprised it doesn't seem to have been a larger contributor to date. Any color you can share, there?
嘿,謝謝。午安。Joe,我有個關於病例、也就是數位病例提交的問題。我想了解你們最近對 CEREC 合作關係目前貢獻度的看法,或你會如何描述到目前為止的成功或進展;另外考量到裝機基數的規模,我有點驚訝它看起來至今並沒有成為更大的貢獻來源。你能否分享一些相關看法?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
You know, Brandon, it really hasn't changed. I think we try to communicate to the market as much as possible, is that we think these -- open source way is the way to go, to make sure that we, our ability to no matter what scanner you're on, if you have the kind of accuracy and capability, that you can submit an Invisalign kind of order. I'm frankly not surprised at what we've seen. I think when you look at Sirona, they've been cautious in the sense of how they bring people on, to make sure of accuracy, and which is really good in the sense of how they can interface with us.
你知道,Brandon,其實沒有什麼改變。我想我們盡可能向市場傳達的是,我們認為這種「開放式」的方式才是正確方向,確保無論你使用哪一種掃描器,只要具備足夠的精準度與能力,就能提交一個 Invisalign 類型的訂單。坦白說,我對我們目前看到的結果並不意外。我認為當你看 Sirona,他們在讓使用者上線的方式上一直很謹慎,以確保精準度;而就他們如何與我們介接而言,這其實是很好的。
And so, right now, it's really no change in the sense of I think what we anticipated prior to Sirona coming on, and what we're seeing right now, but again we feel good about that open source commitment, and we feel good from a North America standpoint in particular, to see the rates of digitized impressions coming in. It's good for our business. It's actually good for customers, because the -- and patients, because of the accuracy of it, and how much faster we can actually turn things around.
因此,就目前而言,從我們在 Sirona 加入之前所預期的,以及我們現在所看到的情況來看,實際上沒有什麼改變;但再次強調,我們對那項開放式平台的承諾感到很有信心,尤其從北美的角度來看,看到數位化印模的導入率持續進來,我們也很振奮。這對我們的業務有利。這其實也對客戶有利,因為——以及對病患也有利,因為其精準度更高,而且我們實際上能更快把流程周轉完成。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
And sorry if this has already been asked, I don't think so, but could you -- you pointed to perhaps the Cadent iTero scanner revenues falling a little bit short of your prior goal for the year. Could you quantify that, and perhaps give us a sense of the magnitude of the backlog, and how long you think it might take to burn off?
另外抱歉如果這題已經有人問過了,我想應該沒有,但你能否——你提到 Cadent iTero 掃描器的營收可能比你先前對今年的目標略低一些。你能量化一下嗎?並且也請你讓我們了解一下積壓訂單的規模大概有多大,以及你認為需要多久才能消化完?
David White - CFO
David White - CFO
Yeah, Brandon. So, you know, when we ended 2015, we had more than six months of backlog on the iTero scanner, and that number still holds true today, notwithstanding the fact that we -- you know, our revenues in that business were up significantly in Q1 and we're almost doubling the business. In the January call, we talked about our expectations of that business perhaps doubling this year, and I think that might have, given where we are today with some production capacity constraints and so forth, that might have been a little more optimistic by maybe 10% or so. And we hope to work through those constraints, and work down the backlog, you know, as we continue to ship product throughout the balance of the year.
好的,Brandon。所以,你知道,2015 年結束時,我們在 iTero 掃描器上有超過六個月的積壓訂單,而即使考量到——你知道——我們該業務在第一季營收大幅成長、業務規模幾乎翻倍,這個數字到今天仍然成立。在一月的電話會議上,我們談到對該業務今年可能翻倍的預期;但以我們目前的狀況來看,受到一些產能限制等等因素影響,那個預期可能稍微樂觀了一點,大概高估了 10% 左右。我們希望能解決這些限制,並在今年剩餘期間持續出貨的同時,把積壓訂單逐步消化掉。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Thank you.
謝謝。
Operator
Operator
Thank you. Our next question comes from Matthew O'Brien from Piper Jaffray.
謝謝。下一題來自 Piper Jaffray 的 Matthew O'Brien。
Matt O'Brien - Analyst
Matt O'Brien - Analyst
Hi guys, thanks for taking the questions. So, you guys have seen impressive North American growth over the last four quarters. How much can you attribute that to the stratification of the sales force?
嗨,各位,謝謝讓我提問。所以,你們在過去四個季度看到北美非常亮眼的成長。你們認為其中有多少可以歸因於銷售團隊的分層配置?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I think it's not a binary answer, Matt, on this whole thing, is I think the stratification was helpful when you define that stratification is, you know, we're focused on really high-end orthos, what we call our stem account, and then how we've allowed our territory managers to go across orthodontics into also GP. That's been an efficient alignment, but we've also put a significant number of more resources into the field also, and so there is, there's a multiplier there in the sense of the customers we're touching and how we're spreading the workforce. So, I think those two main variables, it's hard to pull apart how much each was effective, but we know that both of them have been effective in the sense of allowing us more customer time and placing reps in front of high user kind of accounts, that really need different types of things than some of the newer users or smaller users do.
Matt,我認為這不是一個非黑即白的答案。我想分層配置確實有幫助;所謂分層配置是指——你知道——我們聚焦在真正高端的矯正醫師,也就是我們所稱的重點(stem)客戶,並且我們也讓區域經理能從矯正領域延伸到一般牙科(GP)。這是一種有效率的配置;但同時我們也在前線投入了顯著更多的資源,所以在我們接觸到的客戶數量以及人力配置的擴散上,確實有一種乘數效果。因此,我認為這兩個主要變數很難拆開來量化各自的效果,但我們知道兩者都有效:讓我們有更多與客戶互動的時間,並把業務代表放在高使用量的帳戶前;這些帳戶真正需要的東西,與一些新使用者或小型使用者所需要的不同。
Matt O'Brien - Analyst
Matt O'Brien - Analyst
Great. And also, I apologize if you guys have maybe asked this or answered this already, but single arch was a big growth last quarter. How much did that contribute to the GP segment this quarter? Thanks.
很好。另外,如果你們可能已經被問過或回答過,我先致歉;但單顎(single arch)在上一季是很大的成長動能。這一季它對 GP(一般牙科)客群的貢獻有多少?謝謝。
David White - CFO
David White - CFO
So, good question. You know, as we looked at it, if you look at the single arch and you look at even the pricing actions we took last -- a year ago in Q2, where we lowered the pricing on both the E5 and the E10, we changed the staff discount program, and so forth. As we look at it now, we're seeing great traction on those products. I mean, they're growing well, and much faster than what the rest of our business is on a volume basis. Maybe not the same rate on the revenue side, but certainly on a volume basis, they're growing at a rate faster than what our full products are. And when you look at it on a quarter-over-quarter basis, or I should say a year-over-year basis, it's probably about 3 points of growth, when you compare it year-over-year.
這是個好問題。你知道,當我們來看,如果你看單顎(single arch),以及我們在——一年前第二季——所採取的定價措施:我們下調了 E5 和 E10 的價格、調整了員工折扣方案等等。以目前來看,我們看到這些產品的推進力非常好。我的意思是,它們成長得很好,而且以出貨量來看,成長速度遠快於我們其他業務。在營收面可能沒有同樣的成長率,但在量的面向,它們的成長率確實高於我們完整產品線。如果以季對季——或者我應該說年對年——來看,與去年同期相比,大概貢獻了約 3 個成長點。
Matt O'Brien - Analyst
Matt O'Brien - Analyst
Great, thank you very much.
很好,非常感謝。
Operator
Operator
Thank you. Our next question comes from Chris Lewis from Roth Capital Partners.
謝謝。下一題來自 Roth Capital Partners 的 Chris Lewis。
Shirley Stacy - VP, Corporate Communication & Investor Relations
Shirley Stacy - VP, Corporate Communication & Investor Relations
Hey Chris, are you there?
嘿,Chris,你在線上嗎?
Chris Lewis - Analyst
Chris Lewis - Analyst
I'm here, can you hear me?
我在,你聽得到我嗎?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Yes, we've got you, Chris.
是的,我們聽得到你,Chris。
Chris Lewis - Analyst
Chris Lewis - Analyst
Okay, great. Joe, you mentioned you're beginning to see some progress with teen in international markets. Can you talk about what's starting to drive that progress?
好的,很好。Joe,你提到你開始看到在國際市場的青少年(teen)業務有一些進展。你能談談是什麼開始推動這些進展嗎?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
You know, Chris, again, this is on the subjectivity to my comment here, but I think if you look at the history, particularly in North America, we've had a history here of years of people thinking we really, in orthodontics, not thinking we could do teens. As we go overseas, I don't think we're burdened with that mythology as much, because obviously we changed the type of malocclusions we could do. We moved into teens pretty well, and we've changed our portfolio to address that. I just think there's less inertia to overcome overseas, than maybe what we've had in North America over the years, is my guess.
你知道,Chris,再次強調,這是我個人主觀的看法;但我想如果回顧歷史,特別是在北美,我們多年來一直有一種歷史:大家在矯正領域認為我們——不太認為我們能做青少年病例。當我們走向海外時,我不覺得我們同樣背負那種迷思,因為很明顯我們已經改變了我們能處理的咬合不正類型。我們在青少年市場推進得相當不錯,也調整了我們的產品組合來因應。我猜海外需要克服的慣性比北美多年來的情況要小一些。
I mean, obviously what we're going to have to do, is double back in North America and push a lot harder in the sense of our capability in that area now, to overcome I think some history that has existed there.
我的意思是,很明顯我們接下來必須回到北美,並在我們現在於該領域的能力上更用力推進,以克服我認為過去一直存在的一些歷史包袱。
Chris Lewis - Analyst
Chris Lewis - Analyst
On the Additional Aligners program, it's been around I think nine months since you implemented that. I was hoping you could take a minute and kind of talk about it, if you're starting to see ordering patterns and your customer behavior in terms of utilization rates being impacted from that program?
關於 Additional Aligners(額外牙套)計畫,自你們導入以來我想大概已經九個月了。我希望你能花一點時間談談:你們是否開始看到下單模式,以及客戶在使用率方面的行為,受到這個計畫的影響?
David White - CFO
David White - CFO
Okay. Yes, Chris, when we look at the impact of additional aligners, we look at it over many years. We see increasing usages of additional aligners over time, and primarily that's the result of a number of factors -- the fact that we're treating more complex cases, the fact that our mix is shifting a little bit from the standpoint that international is growing faster than what North America is, since they treat typically more complex cases than what we do here in North America. That's kind of shifting some of that. But, when we look at all those usage rates, we don't see any particular aberration in those rates that we can specifically attribute to the change in the policy.
好的。是的,Chris,當我們看額外牙套的影響時,我們是以多年尺度來觀察。我們看到額外牙套的使用量隨時間增加,而這主要是多項因素造成的——包括我們正在治療更複雜的病例;以及從組合面來看,我們的結構也有些轉移:國際市場成長快於北美,而他們通常治療的病例比我們在北美更複雜。這些因素會帶來一些結構性的移動。但是,當我們檢視所有這些使用率時,我們沒有看到任何特別的異常,能夠明確歸因於政策變更。
What we know is, when we talk to doctors, they love it. They're appreciative of the fact that it's easier for them to practice with us. They don't have to be constantly thinking in the back of their mind -- if I submit a request for additional aligners, am I going to pay for this one or not? So, we don't -- when we look at the data, we don't actually see anything that shows an aberration. It's all pretty much qualitative, and we know that it's one of the factors that we believe is driving the record ortho utilization we're seeing right now.
我們知道的是,當我們和醫師交流時,他們很喜歡這個計畫。他們很感謝這讓他們與我們合作時更容易執業。他們不必一直在心裡想——如果我提出額外牙套的申請,我到底要不要為這一套付費?所以,我們——從數據來看——其實沒有看到任何顯示異常的跡象。這幾乎都是質性的回饋;而我們也知道,這是我們認為正在推動目前創紀錄矯正使用率的因素之一。
Utilization last quarter, Q1, was 10.4, and it's one piece of the whole puzzle, I think.
上一季(第一季)的使用率是 10.4,我認為這只是整個拼圖中的一塊。
Chris Lewis - Analyst
Chris Lewis - Analyst
Okay. Thanks for the time.
好的。謝謝你撥冗。
Operator
Operator
Thank you. Our next question comes from Jon Block from Stifel.
謝謝。下一個問題來自 Stifel 的 Jon Block。
Jon Block - Analyst
Jon Block - Analyst
Great, thanks, and good afternoon, guys. Maybe two or three. The first one, Joe, I believe for you -- on the teen market, I think you guys gave some metrics. Teen's up about 22%, trailing 12 months, but it is lagging adult and you mention the average teen age around 15 years old, but of course a lot of teens are out there getting orthodontic care at 11 to 14. So I guess the question is, can you go younger with the current product, or do you need something more specific to mix dentition and tracking compliance, etc.?
太好了,謝謝,大家午安。我可能有兩到三個問題。第一個,Joe,我想是問你——關於青少年市場,我記得你們提供了一些指標。青少年在過去 12 個月約成長 22%,但仍落後於成人;你們也提到青少年的平均年齡約 15 歲,但當然很多青少年在 11 到 14 歲就開始接受齒顎矯正治療。所以我想問的是:以目前的產品,你們能把年齡往更低延伸嗎?還是需要更針對混合齒列、配戴依從性追蹤等需求的產品?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Jon, I think you know the answer to that question. You know that. (laughter) But I think, honestly, one part of the practical side of me, Jon, says that our teen utilization rate in the 20% to 25% range, depending on how you look at it, is really insufficient given the market is 75% teens. And so, regardless of how young you want to move back into the teen segment, we have plenty of opportunity when you look at complete dentition above 13 years old. So, we should be able to get at, regardless of that kind of approach. But obviously, our R&D is focused on how we can go back and look at what I call morphology changes, rather than just moving teeth, it's actually moving things. And you know, obviously we have some clinical trials in the marketplace in that area to see how well our appliances can fit in that particular area, and we're optimistic about it.
Jon,我想你知道這個問題的答案。你知道的。(笑聲) 不過老實說,Jon,我務實的一面認為,我們青少年使用率大約在 20% 到 25%(視你怎麼看而定),以市場有 75% 是青少年來說,這其實遠遠不夠。因此,不論你想把青少年區間往更年輕推進多少,光是看 13 歲以上、恆齒列完整的族群,我們就有很大的機會。所以,不管採取哪種方式,我們都應該能切入。但很明顯,我們的研發重點在於如何回頭去看我所稱的形態(morphology)變化——不只是移動牙齒,而是實際在移動結構。而且你也知道,我們在那個領域已經有一些臨床試驗在市場上進行,來看看我們的矯治器在那個特定領域的適配性如何;我們對此抱持樂觀。
Jon Block - Analyst
Jon Block - Analyst
Okay, and the next two questions I promise I really don't know. So, the first one, David, for you -- you mentioned maybe on Cadent, more optimistic by 10%. I just want to make sure I understand what you meant. So, if Cadent revs were going to roughly double this year, which was the initial guidance, that was an increment of $45 million. I believe you're saying maybe it's $4 million or $5 million too high? Is that correct? And then the second part is, do you make up that $4 million or $5 million shortfall to still keep your, I think it was low-to-mid 20% revenue guidance for the year? And then I've just got one more.
好的,接下來兩個問題我保證我真的不知道。第一個,David,問你——你提到 Cadent 可能樂觀了 10%。我只是想確認我理解你的意思。所以如果 Cadent 的營收今年原本指引是大約翻倍,那相當於增加 4,500 萬美元。我理解你是在說可能高估了 400 萬到 500 萬美元?是這樣嗎?第二部分是:你們是否會在其他地方補回這 400 萬到 500 萬美元的缺口,以維持你們今年我記得是低到中 20% 的營收指引?然後我還有最後一個問題。
David White - CFO
David White - CFO
So, I think the net of it all is that our revenue guidance is roughly intact. We'll make it up elsewhere, either through pricing or through other things that were built into that plan.
我想整體而言,我們的營收指引大致維持不變。我們會在其他地方補回來,可能透過定價或透過原本計畫中已納入的其他項目。
Jon Block - Analyst
Jon Block - Analyst
Okay. And then, just the very last one, you guys gave some interesting metrics on sort of the percent of high-volume guys that own a scanner, and there's a lot of them, and we've done work showing the average scanner user does a lot more cases than your overall average. But, this brings back into question sort of the chicken or egg. So, are there any metrics that you can give, even at a high level, of what someone looks like before they get a scanner and then where they go six, 12 or 18 months after they bring it into their practice? Thanks, guys.
好的。然後最後一個,你們提供了一些很有意思的指標,像是高量醫師中擁有掃描器的比例,而且數量不少;我們也做過研究,顯示平均而言,掃描器使用者的案例數遠高於你們整體平均。但這又回到「先有雞還是先有蛋」的問題。所以你們能否提供一些指標(即使是高層次的),說明某位醫師在購買掃描器之前是什麼樣子,以及在把掃描器導入診所後 6、12 或 18 個月會變成什麼樣?謝謝各位。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Jon, we don't -- we're obviously looking at that. Our penetration rates are being furthered right now. You've got to look at ortho differently than you do GPs in that sense, but we really don't have anything definitive to share with you yet that would say, you buy a scanner you automatically do more Invisalign. We're not ready to say that yet.
Jon,我們目前沒有——我們當然正在研究這件事。我們的滲透率現在仍在持續推進。在這方面,你必須用不同於一般牙醫(GP)的方式來看矯正科;但我們目前還沒有任何可以明確跟你分享的結論,能說「你買了掃描器就一定會做更多 Invisalign」。我們還沒準備好這麼說。
Jon Block - Analyst
Jon Block - Analyst
Okay, perfect. Thanks for your time, guys.
好的,完美。謝謝你們的時間。
Operator
Operator
Our next question comes from Richard Newitter from Leerink Partners.
下一個問題來自 Leerink Partners 的 Richard Newitter。
Unidentified Participant
Unidentified Participant
Hi, this is Robby in for Rich. Can you hear me?
你好,我是 Robby,代替 Rich。你們聽得到我嗎?
Shirley Stacy - VP, Corporate Communication & Investor Relations
Shirley Stacy - VP, Corporate Communication & Investor Relations
Hi, Robby, yes.
嗨,Robby,可以,聽得到。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Hey, Robby.
嗨,Robby。
Unidentified Participant
Unidentified Participant
Great, thanks for taking the questions. I had a question, a couple questions, one maybe on the doc training and then another on gross margins.
太好了,謝謝讓我提問。我有幾個問題,一個可能關於醫師訓練,另一個關於毛利率。
First, on the Invisalign doctor training, sequentially it looks like there's a seasonal step-down in North America, but you're flat year-over-year, whereas OUS training steps up sequentially. Hoping you could help explain some of the dynamics behind that, and how we should see training progress throughout the year. And then maybe second, on the gross margins, scanner gross margin of about 45%, where do you think that can go over time? And should we think of sort of 2Q to 4Q at this similar level? Thanks.
首先,關於 Invisalign 醫師訓練,從季對季來看北美似乎有季節性下滑,但年對年持平;而 OUS(美國以外)訓練則季對季上升。希望你們能協助解釋背後的一些動態,以及我們應該如何看待全年訓練的進展。第二個,關於毛利率,掃描器毛利率約 45%,你們認為長期來看可以到什麼水準?而我們是否應該預期第二季到第四季大致維持在類似水準?謝謝。
David White - CFO
David White - CFO
Okay. So, Robby, on the doctors trained, when you look at those statistics you'll notice that typically we train more doctors internationally than what we do in North America, and when you break it down and you look in North America, it's primarily GPs. There are re-engagement of orthos and so forth, but the predominant mix is on the GP side. And in terms of the seasonality of that, we typically have a couple periods during the year where that is higher. Q2 and Q4 are typically the periods during the year that we offer more training, and we try to get more enrollment during those time periods.
好的。Robby,關於受訓醫師數,當你看那些統計會注意到,我們通常在國際市場訓練的醫師數會多於北美;而當你再拆解北美,主要是一般牙醫(GP)。也有矯正科醫師的再啟動(re-engagement)等等,但主要組成仍在 GP 端。至於季節性,我們一年通常有幾個時段會比較高。第二季和第四季通常是我們提供較多訓練的期間,我們也會在那些時段努力提高報名人數。
On the international side, I think it fluctuates less on a quarter-to-quarter basis, and it's probably geared more by our capacity to take on doctors and feel like we've got enough clinical help and so forth to get them launched, and start off on their Invisalign practice. And I don't think we see as much seasonality in terms of how we plan out the international doctor side of it.
在國際市場方面,我認為季度之間的波動較小,更多是取決於我們接納醫師的產能,以及我們是否覺得有足夠的臨床支援等資源,讓他們能順利上線並開始他們的 Invisalign 診療。我不認為我們在規劃國際端醫師訓練時會看到那麼明顯的季節性。
And then the second question was on scanning?
然後第二個問題是關於掃描嗎?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
What were the gross margins on scanners?
掃描器的毛利率是多少?
David White - CFO
David White - CFO
So, the gross margins on scanners, they're in the 45% to 50% type of range and a lot of that is due to when we designed the new iTero Element, we designed it as not only a more feature-rich product than the 2.9, which it replaced, but we designed it a lot for cost reduction. And so, you have a much smaller footprint in terms of physical form factor, you know, that sits in the doctor's office. You have much lower support costs for the product because the wand detaches from the base unit. The training is all done virtually, instead of us actually having to actually hold classes on the training. It's done virtually. The doctor installs it himself, versus us having to send somebody in to do a field install. So, all those things kind of contribute to -- from a business model standpoint, why it's a better gross margin proposition than what the prior version was. Does that answer your question?
掃描器的毛利率大約在 45% 到 50% 的區間,而其中很大一部分原因是:當我們設計新的 iTero Element 時,我們不僅把它設計成比它所取代的 2.9 更具功能性的產品,也在設計上大幅著重於降低成本。因此,在醫師診所內的實體外形尺寸(form factor)占用空間小得多。由於掃描棒(wand)可從主機底座拆卸,產品支援成本也更低。訓練全部改為線上進行,而不是我們必須實體開班授課。是以線上方式完成。醫師可自行安裝,而不是我們必須派人到現場安裝。所以,從商業模式角度來看,這些因素共同促成它相較於前一代版本有更好的毛利率表現。這樣有回答到你的問題嗎?
Unidentified Participant
Unidentified Participant
Yes, it does. And then maybe if I could get one more in? Regarding the 3Shape announcement, sorry if you've mentioned it, I may have missed it. Did you say anything about what you think their install base is, and how many dentists that opened up for you?
是的,確實如此。然後也許我還能再問一個問題嗎?關於 3Shape 的公告,抱歉如果你們已經提過了,我可能漏聽了。你們有沒有提到你們認為他們的裝機基數是多少,以及這為你們打開了多少牙醫客戶?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
No, we didn't, and we're not quite privy to that information either. So, I mean obviously, it's a successful scanner, but there's not an installed base number that's been shared with us.
沒有,我們沒有提到,而且我們也不太掌握那方面的資訊。所以,我的意思是,很明顯那是一款成功的掃描器,但他們並沒有跟我們分享任何裝機基數的數字。
Unidentified Participant
Unidentified Participant
Great, thank you.
很好,謝謝你。
Shirley Stacy - VP, Corporate Communication & Investor Relations
Shirley Stacy - VP, Corporate Communication & Investor Relations
Thanks, Robby.
謝謝你,Robby。
David White - CFO
David White - CFO
Thank you, Robby.
謝謝你,Robby。
Shirley Stacy - VP, Corporate Communication & Investor Relations
Shirley Stacy - VP, Corporate Communication & Investor Relations
Operator, we'll take one more question, please.
接線員,請再讓我們接一個問題。
Operator
Operator
Our last question comes from Jeff Johnson from Robert W. Baird.
我們最後一個問題來自 Robert W. Baird 的 Jeff Johnson。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Thank you. Good evening, guys. Joe, just want to start with you. Hey, how are you all? So Joe, starting with you, on the utilization number, the 10.4 number. Obviously, as you guys said, kind of an all-time high on the North American ortho side. As I'm looking at it, it's also, I think, about the biggest sequential jump up I've seen in that metric as well. So, I want to revisit the point you made about kind of end markets being stable. How much of that sequential improvement maybe is coming from some of the efforts you guys have been putting in the field? A lot of the work we've done, and I'm sure others, but survey work, and that seems like North American dental market has picked up here a bit in the last six months. How much might be tied to those factors, things like that? Just want to focus a little more on that 10.4 number, if possible.
謝謝。各位晚上好。Joe,我想先從你開始。嘿,你們大家都好嗎?所以 Joe,先從你這邊談起,關於使用率的數字,也就是 10.4 這個數字。很明顯,如你們所說,這在北美矯正端算是歷史新高。我在看這個指標時,也覺得這可能是我看過最大的單季環比跳升之一。所以我想回到你提到的終端市場相對穩定這一點。這個環比改善有多少可能來自你們在前線投入的一些努力?我們做了很多工作,我相信其他人也做了,包括一些調查研究,看起來北美牙科市場在過去六個月確實有些回升。這個改善有多少可能與這些因素相關、諸如此類?如果可以的話,我想更聚焦在 10.4 這個數字上。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Jeff, it's a good question, I'll tell you. Again, it's a gray answer, because I think we don't see this definitively. But, I would say, I just look at kind of a constant force from a market standpoint over the last 12 months. And then overall, I think it's really the people that we put in the field. It's obviously, I think some of our, you know, inventions like E5, E6. And frankly when you think about E5, E10, and some of our pricing dynamics on that too, all these things I think have really helped us from a penetration standpoint with those guys. So, I wouldn't necessarily attribute it to a market uptick. I think the market has been very consistent. I think our resource allocation and focus is, I think it'll really help in that sense.
Jeff,這是個好問題,我跟你說。同樣地,答案有點灰色,因為我覺得我們也看不到非常明確的因果。但我會說,從市場角度來看,過去 12 個月的市場力量大致是持續且穩定的。而整體而言,我認為主要是我們派到前線的人員。當然,我想也包括我們的一些創新,例如 E5、E6。坦白說,當你想到 E5、E10,以及我們在那方面的一些定價動態時,我認為這些都確實在滲透率方面幫了我們很大一把。所以,我不會一定把它歸因於市場回升。我認為市場一直都很一致、很穩定。我認為我們的資源配置與聚焦,會在這方面帶來很大的幫助。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
All right, great, and then David, just one question for you on the guidance, or at least on some of the P&L numbers. You mentioned the operating margin, 250 basis point hit I think you said between the Extra Aligner policy and the FX in the quarter. Any chance you could split that out, or disaggregate those two numbers? And then, just want to make sure I've got my gating correct. It seems like the FX drag pretty much goes away starting in the second quarter, and the Extra Aligner policy will at least anniversary through the model starting in the third quarter? Is that the right way to think about those drags?
好,很好。接著 David,我有一個關於指引的問題,或至少是關於一些損益表(P&L)數字。你提到本季營業利益率受到約 250 個基點的衝擊,我想你說是來自 Extra Aligner 政策以及匯率(FX)。有沒有可能把這兩個數字拆開,或分別說明一下?另外,我想確認我對節點(gating)的理解是否正確。看起來匯率的拖累從第二季開始基本上就會消失,而 Extra Aligner 政策至少會在第三季起在模型中完成滿一年(anniversary)?這樣理解這些拖累因素對嗎?
David White - CFO
David White - CFO
So, you know, when you always do these compares, it's always against what you're comparing to. When you're comparing quarter-over-quarter, FX and Additional Aligner is not a big impact on Q2. It's a little bit of a drag, you know, but well, 20 bps or so. When you look at it year-over-year, you see a bigger impact, and like you said, about almost 3 points. Most of that's Additional Aligner, about $8 million of that is Additional Aligner, and like another $2.5 million or so roughly of FX.
所以你知道,做這些比較時,永遠都是相對於你拿來比較的基準。如果你是做季對季比較,匯率和 Additional Aligner 對第二季的影響不大。會有一點拖累,但大概也就 20 個基點左右。如果你看年對年,就會看到更大的影響,如你所說,接近 3 個點。其中大部分是 Additional Aligner;大約 800 萬美元來自 Additional Aligner,另外大概約 250 萬美元左右來自匯率。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Okay, and then the FX component as we go into 2Q, would expect that pretty much on a year-over-year basis we're done with most of those headwinds at this point, you think?
了解。那匯率這一塊,進入第二季後,若以年對年來看,你認為我們此時基本上已經度過大部分逆風了,對嗎?
David White - CFO
David White - CFO
Well, you tell me what exactly (multiple speakers) --
嗯,那你得告訴我你指的到底是什麼(多位講者)--
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Assuming, assuming currency stays stable where it is today?
假設、假設匯率維持在今天這個水準不變?
David White - CFO
David White - CFO
If currency stays flat, the only quote -- headwind -- you might say we have, that we keep calling out, is Additional Aligner. An Additional Aligner, in our discussion about Additional Aligner and its impact, kind of swan songs in Q2 because once we get to Q3, our comparatives will have the full impact in it both ways.
如果匯率持平,唯一可以說的——逆風——我們一直特別點出的,就是 Additional Aligner。Additional Aligner,在我們對 Additional Aligner 及其影響的討論中,算是在第二季進入尾聲,因為一旦到了第三季,我們的比較基期就會在兩邊都完整反映其全部影響。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Got it. Thank you.
明白了。謝謝。
Shirley Stacy - VP, Corporate Communication & Investor Relations
Shirley Stacy - VP, Corporate Communication & Investor Relations
Thanks, Jeff.
謝謝你,Jeff。
David White - CFO
David White - CFO
Thanks, Jeff.
謝謝你,Jeff。
Shirley Stacy - VP, Corporate Communication & Investor Relations
Shirley Stacy - VP, Corporate Communication & Investor Relations
Well, thank you everyone for joining us today. This concludes our conference call. If you have any further questions, please contact Investor Relations. Have a great day.
好的,感謝各位今天加入我們。本次電話會議到此結束。如有任何進一步問題,請聯絡投資人關係部門。祝各位有美好的一天。
Operator
Operator
Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
謝謝。今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。